Floatz logo

Rosuvastatin

Anthracycline-induced Cardiac Toxicity

Shiraz University of Medical SciencesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Anthracycline-induced Cardiac Toxicity cohort.

Asset / SponsorPhaseRating
Dapagliflozin
University Medical Centre Ljubljana
Phase 2CCC
Sotagliflozin
Icahn School of Medicine at Mount Sinai
Phase 2CCC
SFX-01 (SULFORAPHANE STABILIZED WITH .ALPHA. CYCLODEXTRIN)
Texas Tech University Health Sciences Center
Phase 1/2CCC
Allo-Mscs
The University of Texas Health Science Center, Houston
Phase 1CC

Same molecule, other indications

Rosuvastatin is also rated in:

inherited lipid metabolism disorderDormant
A
Indicative ·
81 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative ·
77 / 100
View asset →
cardiovascular disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →